Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 33 of 47

Adverse Effects in Elderly Patients: Placebo Comparisons (1 of 3)

A previously published meta-analysis combined the results from 15 placebo comparisons of aripiprazole, olanzapine, quetiapine, and risperidone comprising a total of 5,204 patients. The investigators found that, when compared with placebo, the risk of death in elderly patients (65 and older) with dementia was elevated during treatment with atypical antipsychotics. For every 100 patients, over a 10- to 12-week course of treatment, 1 death is attributable to the atypical antipsychotic. The strength of evidence for this finding is high.

Typical antipsychotics are also associated with an increased risk of death among dementia patients, as revealed in a review of the literature reporting observational studies that was performed as part of the comparative effectiveness review. Twelve studies with a total of 310,752 patients were reviewed and found to demonstrate that there is an elevated risk of death with both atypical and typical antipsychotics when used to treat patients with dementia. The strength of evidence for this finding is moderate.